Volume 98, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The approach to treatment of visceral leishmaniasis (VL)-HIV co-infection in East Africa has not been systematically examined. Although antiretroviral treatment (ART) should be initiated for all co-infected persons, the extent of ART prescription is not known. We conducted a retrospective cohort study including all VL–HIV co-infected adults at selected referral and district hospitals in northwest Ethiopia from 2010 to 2015. Purposes of the study were to compare the proportion of VL diagnoses made in previously diagnosed HIV-patients versus diagnosis concurrent with HIV diagnosis and to quantify utilization of ART. We included 112 patients and 58 patients at the referral and district hospital, respectively (median age: 30 years, 98% males). Of all VL cases, 56% (63/112) and 19% (11/58) occurred in known HIV patients at the referral and district hospital, respectively, with a median CD4 count at VL diagnosis of 45 cells/µL and 248 cells/µL at the referral and district hospital, respectively. Seventy-six percent (56/44) were on ART at VL diagnosis and nine (12%) started ART after VL diagnosis. The remaining 96 (56%) patients had both infections diagnosed concurrently, with a median CD4 count of 56 and 143 cells/µL at the referral and district hospital, respectively. Among cured patients, ART initiation was 67% and 36% at the referral and district hospital, respectively. A substantial proportion of VL–HIV cases occur while in HIV care, requiring further evaluation of preventive strategies. Among newly diagnosed VL–HIV co-infected patients, ART initiation was low. The reasons, including poor documentation and information exchange, should be assessed.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J, 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.
    [Google Scholar]
  2. Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J, 2014. Visceral Leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis 8: e2869.
    [Google Scholar]
  3. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, Hailu A, 2010. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15: 848855.
    [Google Scholar]
  4. Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN, 2011. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152e158.
    [Google Scholar]
  5. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN, 2008. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 17021709.
    [Google Scholar]
  6. van Griensven J, Ritmeijer K, Lynen L, Diro E, 2014. Visceral leishmaniasis as an AIDS defining condition: towards consistency across WHO guidelines. PLoS Negl Trop Dis 8: e2916.
    [Google Scholar]
  7. WHO, 2010. Control of the leishmaniasis. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March, 2010. WHO technical report series 949. Geneva, Switzerland: World Health Organization.
  8. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J, 2014. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 20: 286299.
    [Google Scholar]
  9. van Griensven J, Diro E, Lopez-Velez R, Ritmeijer K, Boelaert M, Zijlstra E, Hailu A, Lynen L, 2014. A screen and treat strategy targeting visceral leishmaniasis in HIV infected individuals in endemic east-African countries: the way forward? PLoS Negl Trop Dis 8: e3011.
    [Google Scholar]
  10. WHO, 2015. A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities. 2015 revision.Geneva, Switzerland: World Health Organization.
  11. WHO, 2012. WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. Geneva, Switzerland: World Health Organization.
  12. Tweya H et al., 2016. Developing a point-of-care electronic medical record system for TB/HIV co-infected patients: experiences from Lighthouse Trust, Lilongwe, Malawi. BMC Res Notes 9: 146.
    [Google Scholar]
  13. Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL, 2012. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 60 (Suppl 3): S136S144.
    [Google Scholar]
  14. Rangaka MX, Wilkinson RJ, 2013. Isoniazid prevention of HIV-associated tuberculosis. Lancet Infect Dis 13: 825827.
    [Google Scholar]

Data & Media loading...

  • Received : 22 Feb 2017
  • Accepted : 13 Oct 2017
  • Published online : 04 Dec 2017
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error